BJA Advance Access originally published online on September 25, 2008
British Journal of Anaesthesia 2008 101(6):769-773; doi:10.1093/bja/aen270
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations
1 Centre for Haemophilia and Thrombosis, Department of Clinical Biochemistry, Aarhus University Hospital, Brendstrupgaardsvej, 8200 Aarhus N, Denmark
2 Centre for Haemostasis and Thrombosis, St Thomas' Hospital, London, UK
* Corresponding author. E-mail: ingerslev{at}ki.au.dk
Background: Patients experiencing massive haemorrhage are at high risk of developing coagulopathy through loss, consumption, and dilution of coagulation factors and platelets. It has been reported that plasma fibrinogen concentrations may reach a critical low level relatively early during bleeding, calling for replacement fibrinogen therapy. Cryoprecipitate has been widely used in the past, but more recently, a pasteurized fibrinogen concentrate has become available. We audited the effects of fibrinogen concentrate therapy on laboratory and clinical outcome in patients with massive haemorrhage.
Methods: We identified 43 patients over the previous 2 yr to whom a fibrinogen concentrate had been administered as treatment for hypofibrinogenaemia during serious haemorrhage. Platelet count, P-fibrinogen, activated partial thromboplastin time (APTT), prothrombin time (PT), D-dimer, and volume of blood lost were obtained from medical and laboratory records. Numbers of units of red blood cells (RBC), fresh frozen plasma (FFP), and pooled platelet concentrates were recorded before and after fibrinogen substitution.
Results: A significant increase in plasma fibrinogen concentration was observed after fibrinogen concentrate therapy. Platelet counts and fibrin D-dimer values remained unchanged, whereas the APTT and PT improved significantly. Requirements for RBC, FFP, and platelets were significantly reduced. Blood loss decreased significantly.
Conclusions: Off-label substitution therapy with a fibrinogen concentrate generally improved global laboratory coagulation results and as supplementary intervention, appeared to diminish the requirements for RBC, FFP, and platelet substitution in this patient cohort.
Keywords: blood, coagulation; blood, transfusion; complications, coagulopathy; drug delivery; safety, drug
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. C. Sihler and L. M. Napolitano Massive Transfusion: New Insights Chest, December 1, 2009; 136(6): 1654 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bolliger, F. Szlam, R. J. Molinaro, N. Rahe-Meyer, J. H. Levy, and K. A. Tanaka Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model Br. J. Anaesth., June 1, 2009; 102(6): 793 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Moor, T. Woolley, M. Midwinter, C. Fenger-Eriksen, J. Ingerslev, and B. Sorensen Coagulation tests in future studies: what to use? Br. J. Anaesth., May 1, 2009; 102(5): 716 - 717. [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- Coagulation tests in future studies: What to use?
- Paul Moor, et al.
- British Journal of Anaesthesia, 22 Dec 2008 [Full text]
- Re: Coagulation tests in future studies: What to use?
- Christian Fenger-Eriksen, et al.
- British Journal of Anaesthesia, 7 Mar 2009 [Full text]
- Does fibrinogen really result in reduction in transfusion requirements ?
- jean-luc hanouz, et al.
- British Journal of Anaesthesia, 16 Apr 2009 [Full text]